A bite-size podcast brought to you by the International Society of Glomerular Disease. Nephrologists and glomerular disease experts Dr. Kenar Jhaveri (Northwell Health/Hofstra University) and Dr. Koyal Jain (UNC Chapel Hill) take a lighthearted look at the latest research, discuss clinical practice, and interview leaders in glomerular medicine — all in a short enough time to listen on your coffee break.
GN in Ten
Claim This Podcastby International Society of Glomerular Disease
5.0(3 reviews)
20 episodes
Updated Bi-weekly
Accepts GuestsHas SponsorsLocation 🇺🇸
63
Podcast Authority
BetaGoodBased on show quality, social media presence, reviews, charts, and more
Quality72
Social0
YouTube74
Engagement60
Podcast Overview
A bite-size podcast brought to you by the International Society of Glomerular Disease. Nephrologists and glomerular disease experts Dr. Kenar Jhaveri (Northwell Health/Hofstra University) and Dr. Koyal Jain (UNC Chapel Hill) take a lighthearted look at the latest research, discuss clinical practice, and interview leaders in glomerular medicine — all in a short enough time to listen on your coffee break.
Language
🇺🇲
Publishing Since
9/2/2023
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
63
Podcast Authority
BetaGoodBased on show quality, social media presence, reviews, charts, and more
Quality72
Social0
YouTube74
Engagement60
9
Excellent Areas
2
Good Performance
8
Growth Opportunities
excellent
Episode Length
9 minutes
Performing excellently!
good
Episode GUID Consistency
60%
Recommendations available
Unlock the full report to see detailed tips
poor
Publishing Consistency
Every 57 days
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
4 verified contact emails on file for GN in Ten
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 17, 2026
Board Review Bonus 7: Membranous Nephropathy
<p><strong>Board Review Bonus 7: Membranous Nephropathy</strong></p><p>In this "Board Review Bonus" (BRB) episode, hosts <strong>Dr. Kenar Jhaveri</strong> and <strong>Dr. Koyal Jain</strong> deliver a high-yield clinical overview of membranous nephropathy (MN)—a classic, board-favorite cause of nephrotic syndrome. Utilizing a real-world case of a 50-year-old male presenting with heavy proteinuria and severe hypoalbuminemia, they walk through diagnostic dilemmas, pathological clues, and the modern therapeutic landscape. Whether you are studying for the boards or looking to "class-switch" your clinical knowledge from IgG1 to IgG4, this bite-sized episode is packed with essential clinical pearls.</p><p><strong>Key Topics Covered:<br></strong><br></p><ul><li><strong>Epidemiology & Biopsy Basics:</strong> Identifying MN as one of the most common causes of adult nephrotic syndrome. The hosts break down classic pathology features: diffuse GBM thickening on light microscopy, "spikes" on silver stain, granular IgG and C3 immunofluorescence, and subepithelial dense deposits on EM.</li><li><strong>The Antigen Revolution:</strong> A review of how the 2009 discovery of anti-PLA2R antibodies on podocytes transformed the diagnosis of primary MN. They also highlight newer antigens to know for the boards, including NELL-1 (associated with malignancy, medications, and lipoic acid), THSD7A (associated with malignancy), and EXT1/EXT2 (associated with lupus).</li><li><strong>Investigating Secondary Causes:</strong> Why age-appropriate malignancy screening, medication reviews, and infectious workups (syphilis, hepatitis B and C) are essential even in PLA2R-positive cases. Key biopsy clues like "full house" staining or endothelial tubuloreticular inclusions can help tip you off to a secondary etiology.</li><li><strong>The "Koyal-Kenar" Risk Stratification:</strong> Why tracking immunological remission via anti-PLA2R titers is often far more predictive than following proteinuria alone. The hosts outline when to initiate immunosuppression based on GFR decline, severe proteinuria/complications, or stable/rising anti-PLA2R titers.</li><li><strong>Conservative Therapy (The CKD Toolkit):</strong> Standard management including low-sodium diets, maximal RAAS blockade, statins (mindful of CNI interactions), SGLT2 inhibitors, and prophylactic anticoagulation (using apixaban or warfarin) when albumin drops below 2.0–2.5 g/dL.</li><li><strong>The Immunosuppressive Toolkit:</strong> Navigating the "big three" regimens: the highly effective but complex 6-month Modified Ponticelli Regimen, first-line Rituximab (backed by the MENTOR trial), and Calcineurin Inhibitors (useful as a bridge, but limited by high relapse rates). Plus, a sneak peek at obinutuzumab (the Majesty trial) for deeper B-cell depletion.</li></ul><p><strong>Recommended Literature:<br></strong><br></p><ul><li><strong>Fervenza FC, Appel GB, Barbour SJ, et al.</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/31269364/">Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy</a></li><li><strong>Fernández-Juárez G, Rojas-Rivera J, van de Logt AE, et al.</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/33166580/">The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.</a> </li><li><strong>Scolari F, Delbarba E, Santoro D, et al.</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/33649098/">Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial.</a></li><li><strong>The MAJESTY Trial (Obinutuzumab vs Tacrolimus in Primary Membranous Nephropathy):</strong> ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/study/NCT04629248">NCT04629248</a>.</li></ul>
June 16, 2026
Board Review Bonus 6: Hereditary Nephritis
<p><strong>Board Review Bonus 6: Hereditary Nephritis</strong></p><p>In this "Board Review Bonus" (BRB) episode, hosts Dr. Kenar Jhaveri and Dr. Koyal Jain provide a comprehensive clinical overview of hereditary nephritis—also known as Alport syndrome—a complex genetic condition with critical renal and extrarenal implications. From a sneaky real-world case of an 18-year-old female presenting with isolated microscopic hematuria to classic textbook syndromic features , our hosts break down the essential knowledge required for both board preparation and clinical practice.</p><p><br></p><p>The discussion moves beyond the classic X-linked male phenotype to explore autosomal varieties and why thin basement membrane disease (TBMD) is increasingly viewed as part of the Alport spectrum rather than a purely benign entity. Dr. Jain and Dr. Jhaveri emphasize critical management strategies, highlighting why an accurate diagnosis is vital to protect patients from receiving unnecessary and ineffective immunosuppressive therapies.</p><p><br></p><p><strong>Key Topics Covered:</strong></p><ul><li><strong>The Hematuria Differential:</strong> Evaluating a young patient with a family history of hematuria, prioritizing Alport syndrome, thin basement membrane disease, and IgA nephropathy.</li><li><strong>Genetics and Inheritance Patterns:</strong> A detailed look at mutations in the alpha 3, 4, and 5 chains of type IV collagen, spanning X-linked, autosomal recessive, and autosomal dominant variants.</li><li><strong>Clinical and Extrarenal Manifestations:</strong> Identifying the classic trio of kidney involvement, high-pitched sensorineural hearing loss, and ocular abnormalities like anterior lenticonus.</li><li><strong>Biopsy and Pathology Pearls:</strong> Differentiating between simple glomerular basement membrane (GBM) thinning and advanced longitudinal splitting ("basket-weave" lamination) on electron microscopy, alongside the utility of pediatric skin biopsies.</li><li><strong>Clinical Management & Pitfalls:</strong> Navigating first-line RAAS inhibition and SGLT2 inhibitors while strictly avoiding immunosuppressive regimens for secondary FSGS lesions.</li><li><strong>Transplantation Outcomes:</strong> Understanding why Alport syndrome does not recur post-transplant, balanced against the 3% to 4% risk of developing de novo anti-GBM disease in the allograft.</li></ul><p><strong>Recommended Literature:</strong></p><ul><li><a href="https://www.alportuk.org/wp-content/uploads/2014/03/Expert-Guidelines-JAN-2013.pdf">Consensus statement on guidelines for the care of children and adolescents with Alport syndrome.</a></li><li><a href="https://pubmed.ncbi.nlm.nih.gov/22166847/">Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy.</a></li><li><a href="https://pubmed.ncbi.nlm.nih.gov/33094278/">Alport Syndrome: Classification and Management </a></li></ul>
April 29, 2026
Board Review Bonus 5: Renal Amyloidosis
<p><strong>Episode 5: Board Review Bonus: Renal Amyloidosis<br></strong><br></p><p>In this "Board Review Bonus" (BRB) episode, hosts Dr. Kenar Jhaveri and Dr. Koyal Jain provide a comprehensive clinical overview of amyloidosis—a complex and often enigmatic disease with significant renal implications. From the initial "mushy, smudgy" appearance on light microscopy to the precise measurements of electron microscopy, our hosts break down the essential knowledge required for both board preparation and clinical practice.</p><p>The discussion moves beyond the common AL and AA variants to explore rare types like LECT2 and the hereditary forms. Dr. Jain and Dr. Jhaveri emphasize that "the tissue is the issue," highlighting the diagnostic necessity of biopsying the affected organ and the critical role of mass spectrometry in directing therapy.</p><p><strong>Key Topics Covered:<br></strong><br></p><ul><li><strong>Classification of Amyloidosis:</strong> A detailed look at AL, AA, LECT2, and the hereditary variants including ATTR, fibrinogen A alpha-chain, and Apolipoprotein.</li><li><strong>The Diagnostic Workup:</strong> Understanding the utility of Congo red staining, the significance of birefringence, and the institutional variability of fat pad biopsies.</li><li><strong>Electron Microscopy (EM) Pearls:</strong> A guide to differentiating amyloid fibrils from mimics such as fibrillary GN, immunotactoid GN, and cryoglobulinemia based on diameter and arrangement.</li><li><strong>Clinical Management:</strong> Navigating the multidisciplinary approach between nephrology, hematology, and cardiology, including the nuances of RAAS inhibition and diuretic therapy in proteinuric patients.</li><li><strong>Transplantation Outcomes:</strong> Evaluating recurrence rates and survival benefits for different amyloid types post-kidney transplant.<p></p></li></ul><p><strong>Recommended Resources and Literature:</strong></p><ul><li><ul><li><a href="http://www.nephronpower.com/2021/06/concept-map-causes-of-renal-amyloidosis.html"><strong>Visual Aid:</strong> Concept Map: Causes of Renal Amyloidosis – A comprehensive resource for classifying amyloid variants and their underlying triggers (via NephronPower).</a></li><li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3487569/"><strong>Dandona P, et al.</strong> The amyloidoses: clinical features, diagnosis and treatment. Methodist Debakey Cardiovasc J. 2012 Jul-Sep;8(3):3-7. PMC3487569</a></li><li><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12308146/"><strong>Panichella G, et al.</strong> Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift. Heart Fail Rev. 2024. PMC12308146</a></li><li><a href="https://pubmed.ncbi.nlm.nih.gov/29254900/"><strong>Moreno-Martínez P, et al.</strong> LECT2-associated renal amyloidosis (ALECT2): A case report. Nefrologia. 2018 Jan-Feb;38(1):97-99. PMID: 29254900</a></li><li><a href="https://pubmed.ncbi.nlm.nih.gov/8097946/"><strong>Benson MD, et al.</strong> Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. Nat Genet. 1993 Mar;3(3):252-5. PMID: 8097946</a></li></ul></li></ul>
20 total episodes available
Similar Podcasts
Discover related shows you might enjoy
Channel Your Enthusiasm
Channel Your Enthusiasm
KDIGO Conversations in Nephrology
KDIGO Communications
A pinch of salt - A podcast by ERA
European Renal Association
ASN Podcast
American Society of Nephrology
Clinical Journal of the American Society of Nephrology (CJASN)
American Society of Nephrology
Journal of the American Society of Nephrology (JASN)
American Society of Nephrology
Annals On Call Podcast
American College of Physicians
The Curbsiders Internal Medicine Podcast
The Curbsiders Internal Medicine Podcast
JAMA Clinical Reviews
JAMA Network
The Curious Clinicians
The Curious Clinicians
Core IM | Internal Medicine Podcast
Core IM Team
Mayo Clinic Talks
Mayo Clinic
The Clinical Problem Solvers
The Clinical Problem Solvers
Harrison's PodClass: Internal Medicine Cases and Board Prep
AccessMedicine
Kidney Commute
kidneycommute
Deep-dive analytics for GN in Ten
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is GN in Ten?
- How often does this podcast release new episodes?
This podcast updates bi-weekly.
- Where can I listen to this podcast?
This podcast is available on 10 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.